MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.
John H Strickler, Tanios Bekaii-Saab, Andrea Cercek...
https://pubmed.ncbi.nlm.nih.gov/39723627/Actively Recruiting
Led by Seagen, a wholly owned subsidiary of Pfizer · Updated on 2026-07-22
400
Participants Needed
366
Research Sites
130 weeks
Total Duration
Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.
CONDITIONS
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
P
Pfizer CT.gov Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seagen, a wholly owned subsidiary of Pfizer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Tucatinib + trastuzumab + mFOLFOX6 | Standard chemo backbone |
|---|---|---|
| What it is | An investigational first‑line regimen combining the HER2‑targeted agents tucatinib and trastuzumab with mFOLFOX6 chemotherapy in HER2‑positive, RAS wild‑type metastatic colorectal cancer | Standard first‑line chemotherapy backbone of mFOLFOX6 given alone or with bevacizumab or cetuximab |
| Role in trial | Investigational treatment arm evaluated for efficacy and safety | Active comparator arm representing current chemotherapy options |
| Primary use | Test whether adding HER2‑targeted therapy improves outcomes compared with standard chemotherapy | Provide current standard-of-care chemotherapy regimen for comparison |
| How it is given or performed | Tucatinib orally twice daily plus intravenous trastuzumab and mFOLFOX6 chemotherapy delivered per usual schedule | mFOLFOX6 chemotherapy given alone or combined with intravenous bevacizumab or cetuximab per standard dosing |
| Evidence status | Under evaluation in a phase III randomized trial; prior phase II data suggest activity of tucatinib plus trastuzumab in refractory HER2‑positive mCRC | Chemotherapy backbone plus bevacizumab or cetuximab represents current, guideline‑supported first‑line treatment for RAS wild‑type metastatic colorectal cancer |
| Important risks | Safety profile not yet established; tucatinib with trastuzumab may add HER2‑targeting toxicities on top of chemotherapy risks | Standard chemotherapy carries known toxicities such as neuropathy and myelosuppression; adding bevacizumab or cetuximab adds known toxic effects |
| Important limitations | Benefit is unproven until trial completes; added HER2‑targeted agents may increase complexity or side effects | Chemotherapy ± targeted agents may have limited efficacy in HER2‑positive mCRC, driving the need for investigational HER2‑targeted approaches |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 3 years
Participants receive either tucatinib with trastuzumab and mFOLFOX6 or one of the standard care regimens including mFOLFOX6 alone or combined with bevacizumab or cetuximab.
Duration - Up to approximately 6 years
Participants are monitored for progression-free survival, overall survival, side effects, and quality of life for up to about 6 years after treatment starts.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
John H Strickler, Tanios Bekaii-Saab, Andrea Cercek...
https://pubmed.ncbi.nlm.nih.gov/39723627/Seagen, a wholly owned subsidiary of Pfizer
Lead Sponsor